tiprankstipranks
Trending News
More News >
Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
India Market
Advertisement

Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

Compare
0 Followers

Top Page

IN:GUFICBIO

Gufic Biosciences Limited

(GUFICBIO)

Select Model
Select Model
Select Model
Neutral 57 (OpenAI - 4o)
Rating:57Neutral
Price Target:
₹373.00
▲(4.45% Upside)
The overall score reflects strong revenue growth and operational efficiency, offset by high valuation and bearish technical indicators. The lack of earnings call data and corporate events limits additional insights.

Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)

Gufic Biosciences Limited Business Overview & Revenue Model

Company DescriptionGufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.
How the Company Makes MoneyGufic Biosciences Limited generates revenue primarily through the manufacturing and sale of pharmaceutical products. The company's revenue streams include formulations, which encompass a wide range of therapeutic segments such as anti-infectives, critical care, and dermatology. Additionally, Gufic produces active pharmaceutical ingredients (APIs) which are sold to other pharmaceutical companies for drug manufacturing. The company also has a presence in the herbal and consumer healthcare space, offering products that cater to wellness and preventive care. Partnerships with hospitals and healthcare providers, along with a robust distribution network, play a significant role in the company's revenue generation strategy.

Gufic Biosciences Limited Financial Statement Overview

Summary
Gufic Biosciences shows strong revenue growth and operational efficiency, but faces challenges with fluctuating net income and cash flow. The balance sheet is stable but requires careful debt management.
Income Statement
72
Positive
Gufic Biosciences has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2020 to 2025. The gross profit margin and EBIT margin are solid, indicating efficient cost management and operational effectiveness. However, the net profit margin has shown some fluctuations, suggesting potential volatility in net income performance.
Balance Sheet
65
Positive
The company's balance sheet indicates a relatively stable equity position with a consistent increase in stockholders' equity. However, the debt-to-equity ratio is moderately high, which may pose risks if not managed carefully. The equity ratio shows a healthy proportion of equity in the capital structure, enhancing financial stability.
Cash Flow
58
Neutral
Gufic Biosciences exhibits inconsistent free cash flow performance, with notable fluctuations in free cash flow growth rates. The operating cash flow to net income ratio shows variability, suggesting challenges in converting income into cash flow. Despite periods of negative free cash flow, recent improvements indicate potential for recovery.
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2021Dec 2020
Income Statement
Total Revenue8.17B8.20B6.91B8.07B7.79B4.88B
Gross Profit3.68B2.97B2.05B4.07B3.56B2.31B
EBITDA1.48B1.38B1.37B1.48B1.48B857.85M
Net Income819.76M696.50M797.05M861.36M958.40M442.32M
Balance Sheet
Total Assets0.0011.69B8.61B10.93B5.21B3.92B
Cash, Cash Equivalents and Short-Term Investments193.96M290.22M466.87M11.37M116.08M62.01M
Total Debt0.003.36B3.34B3.33B643.87M615.37M
Total Liabilities-5.74B5.68B5.13B5.60B2.52B2.19B
Stockholders Equity5.74B6.01B3.48B5.33B2.69B1.73B
Cash Flow
Free Cash Flow0.00270.96M-2.14B-1.20B187.86M748.51M
Operating Cash Flow0.001.03B-265.87M-74.57M1.06B872.51M
Investing Cash Flow0.00-717.09M-1.91B-1.02B-945.89M-66.93M
Financing Cash Flow0.00-163.26M2.34B823.81M-62.44M-786.18M

Gufic Biosciences Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price357.10
Price Trends
50DMA
370.62
Negative
100DMA
368.17
Negative
200DMA
381.54
Negative
Market Momentum
MACD
-1.19
Positive
RSI
43.95
Neutral
STOCH
38.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 357.1 is below the 20-day moving average (MA) of 364.19, below the 50-day MA of 370.62, and below the 200-day MA of 381.54, indicating a bearish trend. The MACD of -1.19 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 38.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
₹30.49B29.035.99%0.77%2.73%-11.40%
67
Neutral
₹26.78B28.6810.21%0.41%2.12%-25.99%
63
Neutral
₹36.55B42.897.86%-3.45%-23.60%
57
Neutral
₹35.81B57.880.03%2.37%-30.78%
55
Neutral
₹31.42B49.637.19%0.55%1.67%-6.61%
46
Neutral
₹26.33B-23.46-7.22%0.07%-8.28%-246.17%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:GUFICBIO
Gufic Biosciences Limited
357.10
-28.24
-7.33%
IN:HIKAL
Hikal Limited
254.80
-115.36
-31.16%
IN:INDOCO
Indoco Remedies Limited
285.45
-73.49
-20.47%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
103.87
10.05
10.71%
IN:MOREPENLAB
Morepen Laboratories Limited
48.87
-36.31
-42.63%
IN:ORCHPHARMA
Orchid Pharma Limited
720.60
-647.35
-47.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025